ESSA Pharma to Present Preclinical Data for its First Generation of Androgen Receptor N-Terminal Domain Degraders at the 2022 American Association for Cancer Research (AACR) Annual MeetingPRNewsWire • 03/08/22
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2021PRNewsWire • 02/03/22
ESSA Pharma Announces First Patient Dosed in a Phase 1/2 Clinical Trial of EPI-7386 in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate CancerPRNewsWire • 01/19/22
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2021PRNewsWire • 11/18/21
ESSA Pharma Presents at 28th Annual Prostate Cancer Foundation Scientific RetreatPRNewsWire • 10/28/21
ESSA Pharma Announces the Presentation of Preclinical Data Characterizing the Mechanism of Action of EPI-7386PRNewsWire • 10/07/21
Caris Life Sciences and ESSA Pharma Announce Liquid Biopsy Profiling CollaborationPRNewsWire • 10/07/21
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2021PRNewsWire • 08/16/21
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2021PRNewsWire • 05/06/21
ESSA Pharma Announces Clinical Collaboration Agreement with Bayer to Evaluate the Combination of EPI-7386 and Darolutamide in Patients with Metastatic Castration-Resistant Prostate CancerPRNewsWire • 04/28/21
ESSA Pharma Presents Preclinical Data Supporting the Therapeutic Potential of EPI-7386 at the 2021 American Association of Cancer Research (AACR) Annual MeetingPRNewsWire • 04/10/21
ESSA Pharma Announces Exercise of Option in Connection with Recently Completed $130 Million FinancingPRNewsWire • 03/04/21
ESSA Pharma Inc. Reports Results of Annual General and Special Meeting of ShareholdersPRNewsWire • 02/25/21
ESSA Pharma Presents Favorable Initial Phase 1 Clinical Pharmacology Data of EPI-7386 for Advanced Forms of Prostate Cancer at the 2021 ASCO Genitourinary Cancers SymposiumPRNewsWire • 02/11/21